Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages

References

• ABBAS, A. K., MURPHY, K. M., and SHER, A., 1996, Functional diversity of helper T lymphocytes. Nature, 383, 787–793.
   PubMedGoogle Scholar
• AMSELEN, S., DOMB, A. J., and AVLING, C. R., 1992, Lipospheres as a vaccine carrier system: effects of size, charge, and phospholipid composition. Vaccine Research, 1, 383–395.
   Google Scholar
• AMURA, C. R., KAMEI, I., ITO, N., SOARES, M. J., and MORRISON, D. C., 1998, Differential regulation of lipopolysaccharide (LPS) activation pathways in mouse macrophages by LPS-binding proteins. Journal of Immunology, 161, 2552–2560.
   PubMedGoogle Scholar
• BAUMANN, H., and GAULDIE, J., 1994. The acute phase response. Immunology Today, 15,74–88.
   PubMedGoogle Scholar
• BOLTRI, L., CANAL, T., ESPOSITO, P., and CARLI, F., 1995, Relevant factors affecting the formulation and growth of lipid nanospheres suspensions. European Journal of Pharmaceutics and Biopharmaceutics, 41, 70–75.
   Google Scholar
• BOURGUIN, I., CHARDES, T., and Bour, D., 1995, Peritoneal macrophages from C57BL/6 mice orally immunized with Toxoplasma gondii antigens in association with cholera toxin possess an enhanced ability to inhibit parasite multiplication. FEMS Immunology Medicine and Microbiology, 12, 121–126.
   PubMedGoogle Scholar
• FIORENTINO, D. F., ZLomix, A., MOSMANN, T. R., HOWARD, M., and O'GARRA, A., 1991, IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology, 147, 3815–3822.
   Google Scholar
• FLESCH, I. E., and KAUFMANN, S. H. E., 1990, Stimulation of antibacterial macrophage activities by B-cell stimulatory factor 2 (interleukin-6). Infection and Immunity, 58, 269–271.
   PubMedGoogle Scholar
• GASCO, M. R., and MOREL, S., 1990, Lipospheres from microemulsions. Ii Farmaco, 45, 1127–1128.
   Google Scholar
• GASPAR, R., PREAT, V., OPPERDOES, F. R., and ROLAND, M., 1992, Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharmaceu-tical Research, 9, 782–787.
   PubMedGoogle Scholar
• GRUNVALD, E., CHIARAMONTE, M., HIENY, S., WYSOCKA, M., TRINCHIERI, G., VOGEL, S. N., GAZZINELLI, R., and SHER, A., 1996, Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasma gondii. Infection and Immunity, 64, 2010–2018.
   PubMedGoogle Scholar
• ILLum, L., JACOBSEN, L. 0., MULLER, R. H., MAK, E., and DAVIS, S. S., 1987, Surface characteristics and interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials, 8, 113.
   Google Scholar
• JEPPSON, R., and RÔSSNER, S., 1975, The influence of emulsifying agents and of lipid soluble drugs on the fractional removal rate of lipid emulsions from the blood stream of the rabbit. Acta Pharmacologica Toxicollogica, 37, 134–144.
   PubMedGoogle Scholar
• LANGERMANS, J., HAZENBOS, W. L. W., and VAN FURTH, R., 1994, Antimicrobial functions of mononuclear phagocytes. Journal of Immunological Methods, 174, 185–194.
   Google Scholar
• LHERM, C., MULLER, R. H., PUISIEUX, F., and COUVREUR, P., 1992, Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. International Journal of Pharmaceutics, 84, 13–22.
   Google Scholar
• MAASSEN, S., 1994, Solid lipid nanoparticles (SLN)—Vergleichende Phagozytose— und Zytotoxizitätsuntersuchungen an humanen Granulozyten. PhD thesis, University of Kiel, Germany.
   Google Scholar
• MAASSEN, S., FATTAL, E., MULLER, R. H., and COUVREUR, P., 1993a, Cell culture for the asessment of toxicity and uptake of polymeric particulate drug carriers. S.T.P. Pharma Sciences, 3, 11–22.
   Google Scholar
• MAASSEN, S., SCHWARZ, C., MEHNERT, W., LUCKS, J. S., YUNIS-SPECHT, F., MULLER, B. W., and MULLER, R. H., 1993b, Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (SLN). Proceedings of the International Symposium on Controlled Relesase of Bioactive Materials, 20, 489–490.
   Google Scholar
• MOSMANN, T., 1983, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55–63 .
   PubMed Web of Science ®Google Scholar
• MOSMANN, T. R., and COFFMAN, R. L., 1989, Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7,145–173.
   PubMedGoogle Scholar
• MULLER, R. H., and LUCKS, J. S., 1991, German Patent Application P 4131562.6.
   Google Scholar
• MULLER, R. H., MAASSEN, S., SCHWARZ, C., and MEHNERT, W., 1997a, Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. Journal of Controlled Release, 47, 261–269.
   Google Scholar
• MULLER, R. H., MAASSEN, S., WEYHERS, H., SPECHT, F., and LucKs, J. S., 1996, Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. International Journal of Pharmaceutics, 138, 85–94.
   Google Scholar
• MULLER, R. H., MEHNERT, W., LUCKS, J. S., SCHWARZ, C., ZUR MUHLEN, A., WEYHERS, H., FREITAS, C., and RUHL, D., 1995, Solid lipid nanoparticles (SLN)an alternativecolloidal carrier system for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 41, 62–69.
   Google Scholar
• MULLER, R. H., RUHL, D., RUNGE, S., SCHULZE-FORSTER, K., and MEHNERT, W., 1997c, Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharmaceutical Research, 14, 458–462.
   Google Scholar
• MULLER, R. H., RUHL, D., and SCHULZE-FORSTER, K., 1997b, Interaction of differentiated HL60 cells with poloxamer and poloxamine surface modified model drug carriers. European Journal of Pharmaceutical Science, 5,147–153.
   Google Scholar
• RUDT, S., and MULLER, R. H., 1993a, in vitro phagocytosis assay of nano- and microparticles by chemiluminescence. II. Effect of surface modification by coating of particles with poloxamer on the phagocytic uptake. Journal of Controlled Release, 25, 51–59.
   Google Scholar
• RUDT, S., and MULLER, R. H., 1993b, In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. III. Uptake of differently sized surface-modified particles, and its correlation to particle properties and in vivo distribution. European Journal of Pharmaceutical Science, 1, 31–39.
   Google Scholar
• SCHWARZ, C., MEHNERT, W., LUCKS, J. S., and MULLER, R. H., 1993, Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterisation and sterilisation. Journal of Controlled Release, 30, 83–96.
   Google Scholar
• SHNYRA, A., BREWINGTON, R., ALIPIO, A., AMURA, C., and MORRISON, D. C., 1998, Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. Journal of Immunology, 160, 3729–3736.
   PubMedGoogle Scholar
• SIEKMANN, B., and WESTESEN, K., 1992, Submicron-sized parenteral carrier systems based on solid lipids. Pharmacy and Pharmacology Letters, 1, 123–126.
   Google Scholar
• TRINCHIERI, G., 1994, Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood, 84, 4008–4027.
   PubMed Web of Science ®Google Scholar
• VAN FURTH, R., COHN, Z. A., HIRSCH, J. G., HUMPHREY, J. H., SPECTOR, W. G., and LANGEVOORT, H. L., 1972, The mononuclear phagocyte system. A new classification of macrophages and their precursor cells. Bulletin of WHO, 46, 845.
   PubMedGoogle Scholar
• YOUNG, L. S., 1990, Gram-negative sepsis. In Principles and practice of infectious diseases, 3rd edn, edited by G. L. Mandell, R. G. Douglas and J. E. Bennett (New York: Churchill Livingstone), pp. 611–636.
   Google Scholar